Evidence of Endothelial Dysfunction in Patients With Inflammatory Bowel Disease  Idan Roifman, Yichun C. Sun, Jason P. Fedwick, Remo Panaccione, Andre G. Buret, Hongqun Liu, Alaa Rostom, Todd J. Anderson, Paul L. Beck  Clinical Gastroenterology and Hepatology  Volume 7, Issue 2, Pages 175-182 (February 2009) DOI: 10.1016/j.cgh.2008.10.021 Copyright © 2009 AGA Institute Terms and Conditions

Figure 1 IBD patients with CD or UC had significantly reduced PAT index measurements compared with controls (*P < .05, **P < .01), indicative of microvascular endothelial dysfunction. Clinical Gastroenterology and Hepatology 2009 7, 175-182DOI: (10.1016/j.cgh.2008.10.021) Copyright © 2009 AGA Institute Terms and Conditions

Figure 2 IBD patients had significantly reduced SSRH compared with controls (*P < .05, **P < .01), indicative of microvascular endothelial dysfunction. There were no significant differences in macrovascular endothelial dysfunction between IBD patients and controls as assessed by FMD via brachial ultrasound. Clinical Gastroenterology and Hepatology 2009 7, 175-182DOI: (10.1016/j.cgh.2008.10.021) Copyright © 2009 AGA Institute Terms and Conditions

Figure 3 There were no significant differences in PAT index measurements in the 48 IBD patients when divided into those with or without anemia, leukocytosis, or thrombocytosis (see Table 2 for normal values). No significant changes were seen with FMD or SSRH. Clinical Gastroenterology and Hepatology 2009 7, 175-182DOI: (10.1016/j.cgh.2008.10.021) Copyright © 2009 AGA Institute Terms and Conditions

Figure 4 IBD patients who reported significant abdominal pain in the past 30 days had reduced PAT index measurements compared with those who did not (**P < .01). There were no differences in PAT index measurements in IBD patients who reported bleeding in the past 30 days compared with those who did not. No significant changes were seen with FMD or SSRH. Clinical Gastroenterology and Hepatology 2009 7, 175-182DOI: (10.1016/j.cgh.2008.10.021) Copyright © 2009 AGA Institute Terms and Conditions

Figure 5 When IBD patients were divided into those taking a certain form of therapy (yes) or not (no) there were no significant changes in PAT index measurements, however, those on azathioprine (n = 8) or infliximab (n = 3) in general had lower PAT index measurements, but these changes were not significant (P > .05). No significant changes were seen with FMD or SSRH. Clinical Gastroenterology and Hepatology 2009 7, 175-182DOI: (10.1016/j.cgh.2008.10.021) Copyright © 2009 AGA Institute Terms and Conditions